WHO ICTRP trial
The effect of COX-2 Inhibition on Reducing Central Sensitisation of Pain in…
EUCTR2006-000395-32-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2006-000395-32-GB |
|---|---|
| Public title | The effect of COX-2 Inhibition on Reducing Central Sensitisation of Pain in Osteoarthritis |
| Scientific title | The effect of COX-2 Inhibition on Reducing Central Sensitisation of Pain in Osteoarthritis |
| Primary sponsor | King's College London |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | United Kingdom |
| Conditions | Osteoarthritis of the knee |
| Interventions | Trade Name: Arcoxia Product Name: Arcoxia Pharmaceutical Form: Film-coated tablet |
| Registration date | Feb 13, 2006 |
| Target size | 16 |
| Secondary IDs | 2006001;ISRCTN36231538 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: